靶向药物对肺癌脑转移的治疗效果(第2页)
本文共计2859个字,预计阅读时长10分钟。【 字体:大 中 小 】
[参考文献]
[1] 张洪玉. 靶向药物对肺癌脑转移的治疗效果(第2页)[J].中国民康医学,2013,25(7):46-47.
[2] 张向东,郭德鸿,雷震,等.易瑞沙同步脑放疗治疗肺癌脑转移30例临床分析[J].中国医学创新,2012,11(19):16-17.
[3] Richar A.P, Rozemarijin V, Firdaus A, et al. Pulmonary function and CT biomarkers as risk factors for cardiovascular events in male lung cancer screening participants: the NELSON study[J]. Euopean Radiology, 2015,25(1):65-71.
[4] Koichi F, Tetsuo T, Noriyasu U, et al. The preoperative plasma D-dimer level is an independent prognostic factor in patients with completely resected non-small cell lung cancer[J]. Surgery Today, 2015,45(1):63-67.
[5] 秦虹,张科乾,李文花,等.非小细胞肺癌脑转移全脑放疗联合靶向药物治疗系统评价[J].中华肿瘤防治杂志,2015,22(4):300-304.
[6] 曲怡梅,廖国清,刘鹏辉,等.吉非替尼治疗非小细胞肺癌脑转移的临床研究[J].现代肿瘤医学,2012,20(4):735-738.
[7] 刘莲花,杨晓峰,贺方学,等.肺癌脑转移瘤放疗方案比较临床疗效及预后分析[J].中华肿瘤预防杂志,2014,21(2):143-146.
[8] 项莲莲,王中奇.肺癌脑转移的中西医结合治疗进展[J].中华中医药杂志,2015,30(3):809-811.
